Novo nordisk a/s: cagrisema demonstrates superior weight loss in adults with obesity or overweight in the redefine 1 trial

BagsvÆrd, denmark, 20 december 2024 – novo nordisk today announced headline results from redefine 1, a phase 3 trial in the global redefine programme. redefine 1 is a 68-week efficacy and safety trial investigating subcutaneous cagrisema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual components cagrilintide 2.4 mg, semaglutide 2.4 mg and placebo, all administered once-weekly. the trial included 3,417 randomised people with obesity or overweight with one or more comorbidities and a mean baseline body weight of 106.9 kg.
NVO Ratings Summary
NVO Quant Ranking